KYMR · Kymera Therapeutics, Inc. · Stock research

Current Thesis

The narrative leg has not changed: KT-621, a once-daily oral STAT6 degrader aimed at the IL-4/IL-13 axis that injectable biologics own today, with BROADEN2 Phase 2b atopic-dermatitis topline guided "by year-end 2026" after enrollment closed roughly six months early on 2026-06-25 — three days after AbbVie agreed to buy Apogee Therapeutics for $10.9B on 2026-06-22.

What has advanced since the last note is two sessions of tape and nothing else. The 2026-08-19 close of $127.31 marked the 52-week high; 2026-08-21 closed $119.80; the 2026-08-24 close of $121.05 recovered 1.04% of that and sits 4.9% under the high. The three-month price change reads +49.9%, down from +51.9% at the prior reading and +57.9% at the high. RSI(14) is 76.2 against 78.2 on 2026-08-21 — the momentum reading cooled by two points while price went up.

Estimates are frozen. The 24-analyst consensus target is $130.91, the same figure carried since 2026-08-14; the implied upside stockanalysis.com computes against it is 8.15% at $121.05, narrower than the 9.27% it showed at $119.80. That gap moves with the quote, not with the estimates.

The company has published nothing since the 2026-08-05 Q2 results. A check of the StockTitan tape on 2026-08-25 still returns 2026-08-05, 2026-07-28 and 2026-07-27 as the three most recent items — twenty calendar days of silence into the back half of August.

The narrative is saturated. The acceleration window was 2026-06-22 to 2026-06-25. The target-raise wave ran 2026-06-26 (Canaccord $129) through 2026-07-16 (Mizuho $140), then turned two-way: RBC to Sector Perform $115 on 2026-07-13, Deutsche Bank initiating Hold at $120 on 2026-07-30, and a 2026-08-07 cluster at J.P. Morgan $121, Bank of America $123 (cut from $125) and Wells Fargo $116. Piper Sandler's 2026-08-20 maintain at $140 is the most recent action on the ratings table as of 2026-08-25 and it left the average untouched.

Bullish and bearish views on Kymera Therapeutics, Inc.

The model's bull view on Kymera Therapeutics, Inc. (KYMR), in brief: BROADEN2 runs to the clock set on 2026-06-25: roughly 200 patients aged 12–75 with moderate-to-severe atopic dermatitis, three KT-621 doses against placebo over 16 weeks, primary endpoint percent change from baseline in EASI at Week 16. The bear view: Three of the five most recent brokerage actions carry targets below the 2026-08-19 high of $127.31 — Wells Fargo $116 (2026-08-07), J.P. Morgan $121 (2026-08-07), Bank of America $123 cut from $125 (2026-08-07). Both cases follow in full.

Bull Case

• BROADEN2 runs to the clock set on 2026-06-25: roughly 200 patients aged 12–75 with moderate-to-severe atopic dermatitis, three KT-621 doses against placebo over 16 weeks, primary endpoint percent change from baseline in EASI at Week 16. Phase 3 initiation in AD is guided by mid-2027, subject to regulator discussions.
• The 2026-08-05 quarter converted partnerships into cash: collaboration revenue $65.0M against $11.5M in Q2 2025 and a $31.165M consensus, comprising a $45M Gilead option-exercise fee on KT-200 and a $20M Sanofi milestone on KT-485/SAR447971 entering Phase 1. EPS -$0.62 versus a -$0.72 estimate.
• No financing event has surfaced: cash, equivalents and investments of $1.5B at 2026-06-30, runway reiterated into 2029, no offering alongside the 2026-08-05 results and none on the tape through the 2026-08-25 check — twenty days of a 52-week-high tape that has not been used to print equity.
• The pipeline tightened rather than slipped at the 2026-08-05 update: KT-579, an oral IRF5 degrader, moved from "2H-2026" to Phase 1 healthy-volunteer data in 4Q26; the BREADTH Phase 2b asthma readout stands at late 2027.
• The upper tail of the published target distribution still sits above the last close: B. Riley $155 (2026-06-29), Piper Sandler $140 (2026-08-20), Mizuho $140 (2026-07-16), Barclays $139 (2026-08-06), Stifel $132 (2026-08-13).
• That is a positioning overhang capable of supplying bid on a clean Q4 print.

Bear Case

• Three of the five most recent brokerage actions carry targets below the 2026-08-19 high of $127.31 — Wells Fargo $116 (2026-08-07), J.P. Morgan $121 (2026-08-07), Bank of America $123 cut from $125 (2026-08-07). The 24-analyst average of $130.91 leaves 8.15% between the 2026-08-24 close and where the sell-side collectively marks the name.
• The upgrade cycle stopped in mid-July. RBC downgraded to Sector Perform on 2026-07-13 while raising its target to $115, and Deutsche Bank started coverage at Hold on 2026-07-30. Since then the only action is a maintain.
• There is no scheduled company event between now and the guided readout window. BROADEN2 topline is "by year-end 2026" with no fixed date; the next reporting obligation is the Q3 print, historically early November. A binary with no date can decay for a quarter.
• Q2 R&D expense of $119.5M against $78.4M a year earlier means burn is scaling ahead of the data. The into-2029 runway assumes no plan expansion alongside a mid-2027 Phase 3 build, and a stock within 5% of its 52-week high is the natural window for an ATM or a shelf.
• Revenue quality: the entire $65.0M Q2 line was two non-recurring partner payments. Q3 will be the first quarter without them, and neither had anything to do with KT-621.
• Competitive clock: Sanofi funds Recludix's rival oral STAT6 program while simultaneously partnering Kymera on KT-485. Clean rival Phase 1 data would compress both the differentiation argument and the acquirer list.

Setup & Price Structure

The advance that matters started from the 2026-08-03 close of $100.31 and ran to $127.31 on 2026-08-19 — the 52-week high — before two down sessions to $119.80 on 2026-08-21 and a 1.04% recovery to $121.05 on 2026-08-24. Distance from the high is 4.9%. The shelf that would define a broken structure is the roughly $100 area from early August; nothing between there and the high has been tested twice.

Crowding and positioning observables, stated as observables:

• RSI(14) at 76.2 on 2026-08-24, above 70 through the whole August leg, and 78.2 as recently as 2026-08-21. Price rebounded while the oscillator eased.
• Consensus target $130.91 unchanged since 2026-08-14 across 24 analysts, so upside to the published average is now 8.15% — the number compresses purely as price rises.
• The first reading spanning the run to the high is due around 2026-08-26.
• Beta 1.96 (stockanalysis.com statistics page, 2026-08-04) — the name amplifies the biotech tape in both directions.
• No earnings inside the next 30 days; the last print was 2026-08-05 and the next is expected in early November, so there is no scheduled fundamental checkpoint against a +49.9% three-month move.
• Insider and venture-fund selling runs through Rule 10b5-1 plans adopted in December 2025 and on 2026-03-24, which makes those sales pre-scheduled rather than a discretionary read on price.

Catalyst Calendar (next 30 days)

• ~2026-08-26 (est.) — FINRA short-interest publication covering the 2026-08-14 settlement date. First positioning reading that spans the advance from $100.31 on 2026-08-03 toward the 2026-08-19 high of $127.31.
• ~2026-09-11 (est.) — FINRA short-interest publication covering the 2026-08-31 settlement date. Second post-run reading; separates cover-driven bid from fresh long demand.
• 2026-09-30 — EADV Congress opens in Vienna (runs to 2026-10-03). Kymera delivered a late-breaking KT-621 presentation at EADV on 2025-09-17; no 2026 slot appears on the company tape as of the 2026-08-25 check.

Elapsed catalysts

• No company-scheduled event inside the window. As of 2026-08-25 there is no press release after 2026-08-05, no conference-participation announcement and no data date on the calendar before EADV. (passed 1d ago)

What Would Change Our Mind

The structure that would have to fail is the base built off the 2026-08-03 close of $100.31 — the launch pad for the entire August leg. A weekly close below $100 forfeits it and puts the name back inside the July range, where the two-way analyst action lives. That is the gradeable condition.

Second, the catalyst gap. If the ~2026-11-04 Q3 update again declines to narrow "by year-end 2026" to a month, and EADV opens 2026-09-30 with no Kymera late-breaker, the readout stays undated through an entire quarter while burn runs at the Q2 rate of $119.5M in R&D.

Third, the takeout premium. It was created by AbbVie–Apogee on 2026-06-22. If the September–October window passes with no further dermatology or type-2 immunology bid, that component of the multiple has nothing supporting it.

On the other side: a shelf takedown or ATM utilisation disclosed in the Q3 10-Q would confirm the issuance-into-strength risk, while BROADEN2 topline landing early with Week 16 EASI inside the injectable benchmark range would restart an estimate cycle that has been static since 2026-08-14.

Correlation Notes

• I&I M&A read-through. The re-rating dates to AbbVie's $10.9B Apogee agreement on 2026-06-22, so the name trades with dermatology and type-2 immunology deal flow rather than with its own newsflow — it has had none for twenty days.
• Sanofi cuts both ways. Sanofi paid the $20M KT-485 milestone booked in Q2 2026 and funds Recludix's competing oral STAT6 asset. A Sanofi immunology headline is not directionally predictable for KYMR.
• Injectable comps set the bar. Dupilumab-class Week 16 EASI performance is the benchmark BROADEN2 gets judged against, which links the readout's reception to Regeneron/Sanofi commercial datapoints.

• Partner concentration. Gilead ($45M option exercise on KT-200) and Sanofi are the two names that have written cheques this year; a change in either collaboration re-prices the non-KT-621 half of the story.